 This is a Phase 12 clinical trial to evaluate a new combination of drugs, marizomib MRZ and bevacizumab BEV; Avastin, for the treatment of WHO Grade IV malignant glioma. The study population includes subjects who are in first or second relapse and who have not previously received any bevacizumab or other anti-angiogenic agent or proteasome inhibitor for treatment of malignant glioma. Phase 1 evaluates the combination of MRZ and BEV, while Phase 2 evaluates single-agent MRZ. Part 3 Phase 2 includes a combination MRZ using intra-patient dose escalation, and BEV at a fixed dose. 